Collectively, these observations show that IXA4 treatment induced transient and preferential activation of IRE1/XBP1s signaling in the liver, thus offering an opportunity to test the impact of pharmacologic IRE1/XBP1s activation in the context of obesity. The gene discussed is ERN1; the disease is obesity due to melanocortin 4 receptor deficiency.